Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.

Should DPD analysis be required prior to prescribing fluoropyrimidines?

Yen JL, McLeod HL.

Eur J Cancer. 2007 Apr;43(6):1011-6. Epub 2007 Mar 12. Review.

PMID:
17350823
2.

[Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine].

Boisdron-Celle M, Morel A, Gamelin E.

Ann Biol Clin (Paris). 2010 Jan-Feb;68(1):27-32. doi: 10.1684/abc.2010.0394. Review. French.

PMID:
20146975
3.

A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.

Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer JC, Duffaud F, Richard K, Blanquicett C, Milano G, Blesius A, Durand A, Seitz JF, Favre R, Lacarelle B.

Ther Drug Monit. 2006 Oct;28(5):678-85.

PMID:
17038885
4.

Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.

Amstutz U, Farese S, Aebi S, Largiadèr CR.

J Exp Clin Cancer Res. 2008 Oct 20;27:54. doi: 10.1186/1756-9966-27-54.

5.

Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients.

He YF, Wei W, Zhang X, Li YH, Li S, Wang FH, Lin XB, Li ZM, Zhang DS, Huang HQ, Hu B, Jiang WQ.

J Clin Pharm Ther. 2008 Jun;33(3):307-14. doi: 10.1111/j.1365-2710.2008.00898.x.

PMID:
18452418
6.

Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.

Ezzeldin HH, Lee AM, Mattison LK, Diasio RB.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8699-705.

7.

Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.

Gross E, Ullrich T, Seck K, Mueller V, de Wit M, von Schilling C, Meindl A, Schmitt M, Kiechle M.

Hum Mutat. 2003 Dec;22(6):498.

PMID:
14635116
9.
10.

[Dihydropyrimidine dehydrogenase activity and its genetic aberrations].

Ogura K.

Gan To Kagaku Ryoho. 2006 Aug;33(8):1041-8. Review. Japanese.

PMID:
16912518
11.

Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals.

Seck K, Riemer S, Kates R, Ullrich T, Lutz V, Harbeck N, Schmitt M, Kiechle M, Diasio R, Gross E.

Clin Cancer Res. 2005 Aug 15;11(16):5886-92.

12.

Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.

van Kuilenburg AB.

Eur J Cancer. 2004 May;40(7):939-50. Review.

PMID:
15093568
13.

Known variant DPYD alleles do not explain DPD deficiency in cancer patients.

Collie-Duguid ES, Etienne MC, Milano G, McLeod HL.

Pharmacogenetics. 2000 Apr;10(3):217-23.

PMID:
10803677
14.
15.

Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question.

van Kuilenburg AB.

Cancer Invest. 2006 Mar;24(2):215-7. Review.

PMID:
16537192
16.

[Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase].

Lazar A, Jetter A.

Dtsch Med Wochenschr. 2008 Jul;133(28-29):1501-4. doi: 10.1055/s-2008-1081098. Review. German.

PMID:
18597209
17.

[Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].

Kralovánszky J, Adleff V, Hitre E, Pap E, Réti A, Komlósi V, Budai B.

Magy Onkol. 2007;51(2):113-25. Epub 2007 Jul 29. Hungarian.

18.

Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.

Ofverholm A, Arkblad E, Skrtic S, Albertsson P, Shubbar E, Enerbäck C.

Clin Biochem. 2010 Feb;43(3):331-4. doi: 10.1016/j.clinbiochem.2009.09.024. Epub 2009 Oct 12.

PMID:
19822137
19.

Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.

Lee A, Ezzeldin H, Fourie J, Diasio R.

Clin Adv Hematol Oncol. 2004 Aug;2(8):527-32. Review.

PMID:
16163233
Items per page

Supplemental Content

Write to the Help Desk